Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept maintenance in mCRC
NCT01889680Phase 2Withdrawn
- Sponsor
- NSABP Foundation
- Start
- Nov 2014
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of aflibercept in metastatic colorectal cancer (mCRC), sponsored by NSABP Foundation. Planned start Nov 2014; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01889680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01889680.